Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TELA BioTELA +5.19%56 Debt-to-Equity is -3.57 as of Jun. 2026. GuruFocus rates TELA with a GF Score™ of 56/100 and a GF Value™ of $1.42 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 699 Medical Devices & Instruments companies, TELA Bio ranks worse than 143061.37% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TELA Bio's Debt-to-Equity or its related term are showing as below:
TELA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -25.91 Med: 1.13 Max: 26.99
Current: -3.57
During the past 9 years, the highest Debt-to-Equity Ratio of TELA Bio was 26.99. The lowest was -25.91. And the median was 1.13.
TELA's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.24
vs TELA: -3.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TELA Bio Debt-to-Equity Related Terms
TELA Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TELA Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA vs ARAY, MODD, NSYS: Debt-to-Equity Comparison
For the Medical Devices subindustry, TELA Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TELA Bio Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TELA Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA Bio (TELA) has a Debt-to-Equity of -3.57 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TELA Bio and its competitors. According to the industry distribution chart, TELA Bio ranks #999999 out of 699 companies in the Medical Devices & Instruments industry.
Is TELA Bio's Debt-to-Equity too high?
TELA Bio's current Debt-to-Equity is -3.57. Based on the distribution chart, TELA Bio ranks #999999 out of 699 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TELA Bio has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's Debt-to-Equity compare to ARAY and MODD?
According to the Medical Devices & Instruments industry distribution chart, TELA Bio ranks #999999 out of 699 companies for Debt-to-Equity. This places TELA Bio in the lower half of its industry. The industry median Debt-to-Equity is 0.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TELA Bio and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TELA Bio's current Debt-to-Equity is -3.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Possible Value Trap. The stock's GF Value™ is $1.42, compared to a current price of $0.81 — trading 42.9% below its estimated fair value. The current Debt-to-Equity is -3.57. TELA Bio's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TELA Bio (TELA), the current Debt-to-Equity is -3.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TELA Bio (TELA) Overvalued in 2026?
Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued.
The current stock price of $0.81 is trading 42.9% below its estimated GF Value™ of $1.42.
GuruFocus considers TELA Bio to be Possible Value Trap.
Key valuation signals for TELA:
Debt-to-Equity: -3.57
GF Value™: $1.42 vs. price of $0.81 (42.9% below fair value)
No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
56GF Score
Get the complete analysis for TELA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELA has been successfully added to your 
